Asia Pacific Antibiotics & Antimycotics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Asia Pacific antibiotics & antimycotics market size is expected to reach US$ 40,545.75 million by 2031 from US$ 26,570.38 million in 2023. The market is estimated to record a CAGR of 5.4% from 2023 to 2031.

Executive Summary and Asia Pacific Antibiotics & Antimycotics Market Analysis:

The antibiotics and antimycotics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to the increasing prevalence of bacterial and fungal infections such as pneumonia, urinary tract infections (UTI), sexually transmitted diseases, and skin infections in the region. In addition, increasing strategic initiatives such as product launches, product approvals, and developments by the market players are likely to offer lucrative opportunities for the market growth in the coming years.

Asia Pacific Antibiotics & Antimycotics Market Strategic Insights

Get more information on this report Request Free Sample PDF

Asia Pacific Antibiotics & Antimycotics Market Segmentation Analysis

Key segments that contributed to the derivation of the Asia Pacific antibiotics & antimycotics market analysis are drug class, indication, route of administration, and distribution channel.

• Based on drug class, the Asia Pacific antibiotics & antimycotics market is segmented into penicillin, cephalosporines, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. The cephalosporines held the largest share of the market in 2023.
• Based on indication, the Asia Pacific antibiotics & antimycotics market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. The skin infections held the largest share of the market in 2023.
• Based on route of administration, the Asia Pacific antibiotics & antimycotics market is segmented into oral, topical, and others. The oral held the largest share of the market in 2023.
• Based on distribution channel, the Asia Pacific antibiotics & antimycotics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies held the largest share of the market in 2023.

Asia Pacific Antibiotics & Antimycotics Market Outlook

The growing awareness of fungal infections and their significant health impacts, coupled with initiatives by government and private organizations, is a crucial factor contributing to the antibiotics and antimycotics market growth. The global burden of invasive fungal infections (IFIs) is attributed to their high morbidity and mortality rates, particularly among immunocompromised patients, such as those undergoing chemotherapy or living with HIV/AIDS. According to the Global Action Fund for Fungal Infections (GAFFI) 2023, more than 300 million people worldwide suffer from serious fungal diseases, resulting in approximately 1.5 million deaths annually—more than the combined deaths from malaria and tuberculosis. Such an upsurge in the prevalence of fungal infections has led to increased efforts in mass education and diagnosis, leading to extensive knowledge among healthcare providers and patients about the importance of timely intervention. Innovations in diagnostic techniques such as molecular testing have further enabled the early diagnosis of fungal pathogens, further driving the demand for effective antifungal treatments.

A 10-year road map for the elimination of fungal illnesses was created by the Global Action Fund for Fungal Infections (GAFFI) in 2015, which also outlines the fundamental conditions required for efficient diagnostic delivery. Similarly, the International Society for Human and Animal Mycology (ISHAM), European Centre for Disease Prevention and Control (ECDC), Mycoses Study Group (MSGERC), Asia Fungal Working Group, Fungal Infection Trust, British Mycology Society, and International Mycological Association are among other associations that make efforts to underline the burden of fungal infections, aiding in the prevention, diagnoses, and treatment of these diseases. Every year, September 16–20 is observed as the Fungal Disease Awareness Week (FDAW) to raise awareness of the growing prevalence of fungal illnesses around the world and the need for appropriate action. Such efforts made to bolster the understanding of fungal diseases result in a surge in diagnoses and the number of patients requiring care, which encourages research aimed at developing new and effective antimycotics.

Asia Pacific Antibiotics & Antimycotics Market Country Insights

Based on country, the Asia Pacific antibiotics & antimycotics market comprises China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest share in 2023.

China is experiencing a surging prevalence of fungal and bacterial infections such as UTI, pneumonia, and respiratory infections, which, in turn, is generating the demand for antibiotics and antimycotics for the treatment and management of such conditions. According to the Epidemiology and Infection Journal 2023, ~21.1 million people suffer from community-acquired pneumonia (CAP) every year in China. Furthermore, various pathogens, including bacterial, fungal, and viral, account for 80% of acute respiratory infections among children. A few of the commonly used antibiotics in China are penicillins, fluoroquinolones, cephalosporins, and nitroimidazoles.

The increasing number of strategic initiatives by market players such as product launches, product developments, and product development is expected to create ample opportunities for the market growth during the forecast period. For instance, in September 2024, Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP (GIBF) made a strategic investment of US$ 6.0 million (approximately CHF 5.17 million) in BioVersys to support its clinical trials in China, which will facilitate and accelerate the clinical development of BV100 (carbapenem-resistant Acinetobacter baumannii). In March 2023, Everest Medicines received a New Drug Application (NDA) from the National Medical Products Administration (NMPA) of China for Xerava (eravacycline) for the treatment of complex intra-abdominal infections (cIAI) in adult patients.

Asia Pacific Antibiotics & Antimycotics Market Report Highlights

Asia Pacific Antibiotics & Antimycotics Market Company Profiles

Some of the key players operating in the market are Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Antibiotics & Antimycotics Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners’ conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Asia Pacific Antibiotics & Antimycotics Market Country and Regional Insights